Record Information |
---|
Version | 5.0 |
---|
Status | Expected but not Quantified |
---|
Creation Date | 2012-09-06 15:16:51 UTC |
---|
Update Date | 2022-03-07 02:51:50 UTC |
---|
HMDB ID | HMDB0015034 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Triazolam |
---|
Description | Triazolam is only found in individuals that have used or taken this drug.It is withdrawn in the United Kingdom due to risk of psychiatric adverse drug reactions. This drug continues to be available in the U.S. Internationally, triazolam is a Schedule IV drug under the Convention on Psychotropic Substances.Benzodiazepines bind nonspecifically to bezodiazepine receptors BNZ1, which mediates sleep, and BNZ2, which affects affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine receptors are thought to be coupled to gamma-aminobutyric acid-A (GABAA) receptors, this enhances the effects of GABA by increasing GABA affinity for the GABA receptor. Binding of GABA to the site opens the chloride channel, resulting in a hyperpolarized cell membrane that prevents further excitation of the cell. |
---|
Structure | CC1=NN=C2CN=C(C3=CC=CC=C3Cl)C3=C(C=CC(Cl)=C3)N12 InChI=1S/C17H12Cl2N4/c1-10-21-22-16-9-20-17(12-4-2-3-5-14(12)19)13-8-11(18)6-7-15(13)23(10)16/h2-8H,9H2,1H3 |
---|
Synonyms | Value | Source |
---|
Halcion | ChEBI | DEA no. 2887 | HMDB | Genpharm brand OF triazolam | HMDB | Apo triazo | HMDB | Apo-triazo | HMDB | Apotex brand OF triazolam | HMDB | Gen triazolam | HMDB | Gerard brand OF triazolam | HMDB | Pfizer brand OF triazolam | HMDB | Gen-triazolam | HMDB | Triazolam pfizer brand | HMDB | Trilam | HMDB |
|
---|
Chemical Formula | C17H12Cl2N4 |
---|
Average Molecular Weight | 343.21 |
---|
Monoisotopic Molecular Weight | 342.043901818 |
---|
IUPAC Name | 12-chloro-9-(2-chlorophenyl)-3-methyl-2,4,5,8-tetraazatricyclo[8.4.0.0²,⁶]tetradeca-1(10),3,5,8,11,13-hexaene |
---|
Traditional Name | triazolam |
---|
CAS Registry Number | 28911-01-5 |
---|
SMILES | CC1=NN=C2CN=C(C3=CC=CC=C3Cl)C3=C(C=CC(Cl)=C3)N12 |
---|
InChI Identifier | InChI=1S/C17H12Cl2N4/c1-10-21-22-16-9-20-17(12-4-2-3-5-14(12)19)13-8-11(18)6-7-15(13)23(10)16/h2-8H,9H2,1H3 |
---|
InChI Key | JOFWLTCLBGQGBO-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as 1,2,4-triazolo[4,3-a][1,4]benzodiazepines. These are aromatic compounds containing a 1,4-benzodiazepine fused to and sharing a nitrogen atom with a 1,2,4-triazole ring. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organoheterocyclic compounds |
---|
Class | Benzodiazepines |
---|
Sub Class | 1,4-benzodiazepines |
---|
Direct Parent | 1,2,4-triazolo[4,3-a][1,4]benzodiazepines |
---|
Alternative Parents | |
---|
Substituents | - 1,2,4-triazolo[4,3-a][1,4]benzodiazepine
- Chlorobenzene
- Halobenzene
- Aryl chloride
- Aryl halide
- Monocyclic benzene moiety
- Benzenoid
- Azole
- Heteroaromatic compound
- 1,2,4-triazole
- Ketimine
- Azacycle
- Organic 1,3-dipolar compound
- Propargyl-type 1,3-dipolar organic compound
- Imine
- Organopnictogen compound
- Organic nitrogen compound
- Hydrocarbon derivative
- Organonitrogen compound
- Organohalogen compound
- Organochloride
- Aromatic heteropolycyclic compound
|
---|
Molecular Framework | Aromatic heteropolycyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | Not Available |
---|
Role | |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | 233 - 235 °C | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | 0.018 g/L | Not Available | LogP | 5.5 | Not Available |
|
---|
Experimental Chromatographic Properties | Experimental Collision Cross SectionsAdduct Type | Data Source | CCS Value (Å2) | Reference |
---|
[M+H]+ | CBM | 172.4 | 30932474 |
|
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatized |
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Triazolam GC-MS (Non-derivatized) - 70eV, Positive | splash10-0006-8089000000-80a2c04b55ba4ec57f7d | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Triazolam GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | MS | Mass Spectrum (Electron Ionization) | splash10-0imr-4954000000-75bcea16a1182103168f | 2014-09-20 | Not Available | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental LC-MS/MS | LC-MS/MS Spectrum - Triazolam 35V, Positive-QTOF | splash10-0006-0019000000-c8c0d3cd9a1976505512 | 2021-09-20 | HMDB team, MONA | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Triazolam 10V, Positive-QTOF | splash10-0006-0019000000-1a48dd0b8ad68d4c7152 | 2016-06-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Triazolam 20V, Positive-QTOF | splash10-0006-0019000000-299396e073c781434d64 | 2016-06-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Triazolam 40V, Positive-QTOF | splash10-0ke9-1393000000-9375b44f5c2300bb98ba | 2016-06-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Triazolam 10V, Negative-QTOF | splash10-0006-0019000000-45c89b536091edda4e23 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Triazolam 20V, Negative-QTOF | splash10-0006-0029000000-ff0a3ff2d1d3a8b13088 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Triazolam 40V, Negative-QTOF | splash10-0fai-0390000000-188cc5d505add9b26071 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Triazolam 10V, Positive-QTOF | splash10-0006-0009000000-66a85ec67775de1bf91b | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Triazolam 20V, Positive-QTOF | splash10-0006-0009000000-66a85ec67775de1bf91b | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Triazolam 40V, Positive-QTOF | splash10-03dr-1289000000-ce967160c7f8152bf73c | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Triazolam 10V, Negative-QTOF | splash10-0006-0009000000-3ebd0ee81f9052f5a37b | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Triazolam 20V, Negative-QTOF | splash10-053u-6009000000-48a129158117535fca22 | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Triazolam 40V, Negative-QTOF | splash10-001i-9152000000-8ffd20b7c50c68f2a695 | 2021-10-11 | Wishart Lab | View Spectrum |
|
---|
General References | - Oelschlager H: [Chemical and pharmacologic aspects of benzodiazepines]. Schweiz Rundsch Med Prax. 1989 Jul 4;78(27-28):766-72. [PubMed:2570451 ]
- Rickels K: The clinical use of hypnotics: indications for use and the need for a variety of hypnotics. Acta Psychiatr Scand Suppl. 1986;332:132-41. [PubMed:2883820 ]
- Tokunaga S, Takeda Y, Shinomiya K, Hirase M, Kamei C: Effects of some H1-antagonists on the sleep-wake cycle in sleep-disturbed rats. J Pharmacol Sci. 2007 Feb;103(2):201-6. Epub 2007 Feb 8. [PubMed:17287588 ]
- Veje JO, Andersen K, Gjesing S, Kielgast H: [Prescription of tranquilizers and hypnotics in the municipality of Holbaek]. Ugeskr Laeger. 1989 Aug 21;151(34):2134-6. [PubMed:2773144 ]
- Noguchi H, Kitazumi K, Mori M, Shiba T: Electroencephalographic properties of zaleplon, a non-benzodiazepine sedative/hypnotic, in rats. J Pharmacol Sci. 2004 Mar;94(3):246-51. [PubMed:15037809 ]
|
---|